Mylan Sovaldi Launch

May 05, 2015 02:54 am | Updated 02:54 am IST - HYDERABAD:


Mylan launches Sovaldi tablets in India

Mylan NV on Monday announced that its subsidiary Mylan Pharmaceuticals Pvt. Ltd. had launched Gilead Sciences’ Sovaldi (sofosbuvir 400mg tablets) in India. This follows Gilead, in February this year, appointing Mylan as its exclusive distributor of Sovaldi in the country. According to a release from Mylan, Sovaldi is indicated for treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. An estimated 12 million people are chronically infected with hepatitis C in India. — N. Ravikumar

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.